Azienda Socio Sanitaria Locale N 2 Della Gallura

At Azienda Socio Sanitaria Locale N 2 Della Gallura in Olbia, clinical research in cardiovascular diseases and nutritional and metabolic diseases is focused on people living with type 2 diabetes mellitus and chronic kidney disease. The studies are designed to better understand whether new treatment combinations can improve kidney and heart outcomes while supporting standard care.

• Evaluating whether combined therapy can reduce kidney damage markers more effectively than single treatments
• Assessing treatments aimed at lowering major cardiovascular event risk in patients with diabetes
• Studying therapies that may improve both metabolic control and long-term organ protection

These trials reflect a strong interest in improving treatment effectiveness for patients with overlapping heart, kidney, and diabetes-related conditions.

The site also contributes to immune system disease research through studies in rare inflammatory conditions such as PAPA syndrome. This work explores whether targeted anti-inflammatory treatment can provide meaningful benefit for patients with difficult-to-manage disease.

• Testing a targeted therapy for a rare autoinflammatory syndrome
• Examining symptom control and disease activity in a complex immune-mediated disorder
• Generating evidence to support better treatment choices in rare inflammatory disease

Research in this area helps advance care for uncommon conditions where treatment options remain limited and clinical evidence is still developing.

Another important theme at this hospital/clinic is the study of therapies for type 2 diabetes mellitus with a focus on broader cardiometabolic outcomes. The research is aimed at understanding whether newer treatments can improve cardiovascular protection alongside glucose management.

• Comparing diabetes treatments for their effect on major heart and stroke outcomes
• Exploring whether newer metabolic therapies offer added benefit beyond standard treatment
• Supporting better long-term care for patients at high cardiovascular risk

This line of research brings together cardiovascular and metabolic care, with the goal of improving both disease control and patient outcomes.